As of April 26, 2023, around 81.3 percent of the U.S. population had received at least one dose of a COVID-19 vaccination. This statistic shows the percentage of the population in the United States who had been given a COVID-19 vaccination as of April 26, 2023, by state or territory.

As of December 23, 2022, around 80 percent of the population of the United States had been given at least one dose of a COVID-19 vaccination. This statistic shows the percentage of population in select countries and territories worldwide that had received a COVID-19 vaccination as of December 23, 2022.

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Citywide/6859-spec. COVID-19 vaccinations administered to Chicago residents based on the reported race-ethnicity and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). Vaccination Status Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received. ··People with an original booster dose: Number of people who have a completed vaccine series and have received at least one additional monovalent dose. This includes people who received a monovalent booster dose and immunocompromised people who received an additional primary dose of COVID-19 vaccine. Monovalent doses were created from the original strain of the virus that causes COVID-19. - People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains. Weekly cumulative totals by vaccination status are shown for each combination of race-ethnicity and age group. Note that each age group has a row where race-ethnicity is "All" so care should be taken when summing rows. Vaccinations are counted based on the date on which they were administered. Weekly cumulative totals are reported from the week ending Saturday, December 19, 2020 onward (after December 15, when vaccines were first administered in Chicago) through the Saturday prior to the dataset being updated. Population counts are from the U.S. Census Bureau American Community Survey (ACS) 2019 1-year estimates. For some of the age groups by which COVID-19 vaccine has been authorized in the United States, race-ethnicity distributions were specifically reported in the ACS estimates. For others, race-ethnicity distributions were estimated by the Chicago Department of Public Health (CDPH) by weighting the available race-ethnicity distributions, using proportions of constituent age groups. Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity) who have each vaccination status as of the date, divided by the estimated number of Chicago residents in each subgroup. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group. All coverage percentages are capped at 99%. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. CDPH uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Data reported in I-CARE only include doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that c

Between January 1, 2021 and April 30, 2022 the death rate due to COVID-19 in the United States was about 2,487 per one million population. An analysis published in May 2022 found that if 100 percent of the population in the United States had been vaccinated at this time then the death rate over this period would have been around 1,237 per one million population. It was estimated that a 100 percent vaccination rate could have prevented 318,981 of 641,305 total deaths reported over this period. As of May 2022, around 66 percent of the U.S. population had been fully vaccinated against COVID-19. This table shows the actual death rate due to COVID-19 in the United States between January 2021 and April 2022 compared to the death rate if 100 percent of the population had been vaccinated.

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

NOTE: This dataset replaces two previous ones. Please see below.

Chicago residents who are up to date with COVID-19 vaccines, based on the reported address, race-ethnicity, sex, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE).

“Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria:

People ages 5 years and older: · Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season.

Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine.

This dataset takes the place of two previous datasets, which cover doses administered from December 15, 2020 through September 13, 2023 and are marked has historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Daily-Vaccinations-Chicago-Residents/2vhs-cf6b - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-Age-and-Race-Ethnicity/37ac-bbe3.

Data Notes:

Weekly cumulative totals of people up to date are shown for each combination of race-ethnicity, sex, and age group. Note that race-ethnicity, age, and sex all have an option for “All” so care should be taken when summing rows.

Coverage percentages are calculated based on the cumulative number of people in each race-ethnicity/age/sex population subgroup who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller demographic groupings with smaller populations. Additionally, the medical provider may report incorrect demographic information for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage. All coverage percentages are capped at 99%.

Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Individuals may receive vaccinations that are not recorded in the Illinois immunization registry, I-CARE, such as those administered in another state, causing underestimation of the number individuals who are up to date. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate records for a person and underestimate the number of people who are up to date.

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau 2020 Decennial Census

As of April 26, 2023, the percentage of adults 65 years and older who were fully vaccinated against COVID-19 had reached 94 percent. This statistic presents the percentage of adults 65 years and older in the United States with at least one dose or were fully vaccinated against COVID-19 as of April 26, 2023.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

IntroductionCOVID-19 vaccine inequities have been widespread across California, the United States, and globally. As COVID-19 vaccine inequities have not been fully understood in the youth population, it is vital to determine possible factors that drive inequities to enable actionable change that promotes vaccine equity among vulnerable minor populations.MethodsThe present study used the social vulnerability index (SVI) and daily vaccination numbers within the age groups of 12–17, 5–11, and under 5 years old across all 58 California counties to model the growth velocity and the anticipated maximum proportion of population vaccinated.ResultsOverall, highly vulnerable counties, when compared to low and moderately vulnerable counties, experienced a lower vaccination rate in the 12–17 and 5–11 year-old age groups. For age groups 5–11 and under 5 years old, highly vulnerable counties are expected to achieve a lower overall total proportion of residents vaccinated. In highly vulnerable counties in terms of socioeconomic status and household composition and disability, the 12–17 and 5–11 year-old age groups experienced lower vaccination rates. Additionally, in the 12–17 age group, high vulnerability counties are expected to achieve a higher proportion of residents vaccinated compared to less vulnerable counterparts.DiscussionThese findings elucidate shortcomings in vaccine uptake in certain pediatric populations across California and may help guide health policies and future allocation of vaccines, with special emphasis placed on vulnerable populations, especially with respect to socioeconomic status and household composition and disability.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

As of April 26, 2023, one of the states with the highest percentage of adults 65 years and older who were fully vaccinated against COVID-19 was Vermont with 95 percent. This statistic shows the percentage of adults aged 65 and older in the United States who were fully vaccinated against COVID-19 as of April 26, 2023, by state or territory.

A. SUMMARY This dataset represents the COVID-19 vaccinations given to residents of San Francisco. All vaccines given to SF residents are included, no matter where the vaccination took place (the vaccine may have been administered in San Francisco or outside of San Francisco). The data are broken down by multiple demographic stratifications. This dataset also includes COVID-19 vaccinations given to SF residents by the San Francisco Department of Public Health (SFDPH).

Data provides counts for residents who have received at least one dose, residents who have completed a primary vaccine series, residents who have received one or two monovalent (not bivalent) booster doses, and residents who have received a bivalent booster dose. A primary vaccine series is complete after an individual has received all intended doses of the initial series. There are one, two, and three dose primary vaccine series.

B. HOW THE DATASET IS CREATED Information on doses administered to those who live in San Francisco is from the California Immunization Registry (CAIR2), run by the California Department of Public Health (CDPH). The information on individuals’ city of residence, age, race, and ethnicity are also recorded in CAIR and are self-reported at the time of vaccine administration.

In order to estimate the percent of San Franciscans vaccinated, we provide the 2016-2020 American Community Survey (ACS) population estimates for each demographic group.

C. UPDATE PROCESS Updated daily via automated process

D. HOW TO USE THIS DATASET San Francisco population estimates for race/ethnicity and age groups can be found in a view based on the San Francisco Population and Demographic Census dataset. These population estimates are from the 2016-2020 5-year American Community Survey (ACS).

Before analysis, you must filter the dataset to the desired stratification of data using the "overall_segment" column.

For example, filtering "overall_segment" to "All SF Residents by Age Bracket, Administered by All Providers" will filter the data to residents whose vaccinations were administered by any provider. You can then further segment the data and calculate percentages by Age Brackets.

If you filter "overall_segment" to "All SF Residents by Race/Ethnicity, Administered by DPH Only", you will see the race/ethnicity breakdown for residents who received vaccinations from the San Francisco Department of Public Health (SFDPH).

If you filter "overall_segment" to "All SF Residents by Age Group, Administered by All Providers" you will see vaccination counts of various age eligibility groups that were administered by any provider.

To count the number of individuals vaccinated (with any primary series dose), use the "total_recipients" column. To count the number of individuals who have completed their primary vaccine series, use the "total_series_completed" column. To count the number of primary series doses administered (1st, 2nd, 3rd, or single doses), use the "total_primary_series_doses" column.

To count the number of individuals who received one or two monovalent (not bivalent) booster doses, use the "total_booster_recipients" and "total_2nd_booster_recipients" columns. To count the number of individuals who received their first bivalent booster dose, use the "total_bivalent_booster_recipients" column. To count the number of monovalent (not including bivalent) or bivalent booster doses administered, use the "total_booster_doses" or "total_bivalent_booster_doses" columns.

E. ARCHIVED DATA A previous version of this dataset was archived on 10/27/2022. For historical purposes, you can access the archived dataset at the following link:

ARCHIVED: COVID-19 Vaccine Doses Given to San Franciscans by Demographics

F. CHA

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

Monthly Cumulative Number and Percent of Persons Who Received ≥1 Influenza Vaccination Doses, by Flu Season, Age Group, and Jurisdiction

• Influenza vaccination coverage for children and adults is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. More information about the IIS can be found at https://www.cdc.gov/vaccines/programs/iis/about.html.

• Influenza vaccination coverage estimate numerators include the number of people receiving at least one dose of influenza vaccine in a given flu season, based on information that state, territorial, and local public health agencies report to CDC. Some jurisdictions’ data may include data submitted by tribes. Estimates include persons who are deceased but received a vaccination during the current season. People receiving doses are attributed to the jurisdiction in which the person resides unless noted otherwise. Quality and completeness of data may vary across jurisdictions. Influenza vaccination coverage denominators are obtained from 2020 U.S. Census Bureau population estimates.

• Monthly estimates shown are cumulative, reflecting all persons vaccinated from July through a given month of that flu season. Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.

• Because IIS data contain all vaccinations administered within a jurisdiction rather than a sample, standard errors were not calculated and statistical testing for differences in estimates across years were not performed.

• Laws and policies regarding the submission of vaccination data to an IIS vary by state, which may impact the completeness of vaccination coverage reflected for a jurisdiction. More information on laws and policies are found at https://www.cdc.gov/vaccines/programs/iis/policy-legislation.html.

• Coverage estimates based on IIS data are expected to differ from National Immunization Survey (NIS) estimates for children (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-coverage-race.html) and adults (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-adult-coverage.html) because NIS estimates are based on a sample that may not be representative after survey weighting and vaccination status is determined by survey respondent rather than vaccine records or administrations, and quality and completeness of IIS data may vary across jurisdictions. In general, NIS estimates tend to overestimate coverage due to overreporting and IIS estimates may underestimate coverage due to incompleteness of data in certain jurisdictions.

This site provides historical data beginning June 14, 2023, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Percent of Total Population Who Are Up to Date with COVID-19 Vaccines”

Definition for Up to Date: For surveillance purposes people are ‘Upto Date’ with COVID-19 vaccines based on the following criteria:

People ages 6 years and older: Are up to date if they received 1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine.

Children ages 6 months to 5 years who received the Pfizer-BioNTech COVID-19 vaccine: Are up to date if: At ages 6 months to 4 years, they received 3 COVID-19 vaccine doses, including at least 1 updated COVID-19 dose; at age 5 years, they received at least 1 updated COVID-19 vaccine dose.

Children ages 6 months to 5 years who received the Moderna COVID-19 vaccine: Are up to date if they received 2 Moderna COVID-19 vaccine doses, including at least 1 updated COVID-19 vaccine dose.

People who are unable or choose not to get a recommended mRNA vaccine: Are up to date if they receive the Novavax COVID-19 vaccine doses approved for their age group.

CDC uses US Census estimates for the total populations within each specified demographic group regardless of prior vaccination status as denominators.

Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Chicago residents who are up to date with influenza vaccines, based on the reported address, race-ethnicity, sex, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). “Up to date” refers to individuals aged 6 months and older who have received 1+ doses of influenza vaccine during the current season, defined as the beginning of July (MMWR week 27) through the end of the following June (MMWR week 26). Data Notes: Weekly cumulative counts and coverage percentages of people up to date are shown for each combination of race-ethnicity, sex, and age group. Note that race-ethnicity, age, and sex all have an option for “All” so care should be taken when summing rows. Weeks begin on a Sunday and end on a Saturday. Coverage percentages are calculated based on the cumulative number of people in each race-ethnicity/age/sex population subgroup who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller demographic groupings with smaller populations. Additionally, the medical provider may report incorrect demographic information for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage. All coverage percentages are capped at 99%. The Chicago Department of Public Health (CDPH) uses the most complete data available to estimate influenza vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Influenza vaccine administration is not required to be reported in Illinois, except for publicly funded vaccine (e.g., Vaccines for Children, Section 317). Individuals may receive vaccinations that are not recorded in I-CARE, such as those administered in another state, or those administered by a provider that does not submit data to I-CARE, causing underestimation of the number individuals who received an influenza vaccine for the current season. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to influenza, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=flu. Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau 2020 Decennial Census

Among those in the U.S. who received a COVID-19 vaccination from December 14, 2020 to January 14, 2021, 26 percent were aged 50 to 64 years. This statistic shows the distribution of people who received a COVID-19 vaccination in the United States from Dec. 14, 2020 to Jan. 14, 2021, by age.

As of 10/27/2022, this dataset will no longer update. To continue to access updated vaccination metrics given to SF residents, including newly added bivalent boosters, please navigate to the following page: COVID-19 Vaccinations Given to SF Residents Over Time.

A. SUMMARY This dataset represents the COVID-19 vaccinations given to San Franciscans over time. All vaccines given to people who live in San Francisco are included, no matter where the vaccination took place (the vaccine may have been administered in San Francisco or outside of San Francisco).

B. HOW THE DATASET IS CREATED Information on doses administered to those who live in San Francisco is from the California Immunization Registry (CAIR), run by the California Department of Public Health (CDPH).

C. UPDATE PROCESS Updated daily via automated process

D. HOW TO USE THIS DATASET Different vaccines have different dosage requirements. For example, the Moderna and the Pfizer vaccines require two doses in order for a resident to complete their primary vaccine series (as of December 21, 2021). Each dose is recorded separately in its respective dataset column. Other vaccines, such as Johnson & Johnson, would only require a single dose for a resident to complete their primary vaccine series (as of December 21, 2021). The Pfizer vaccine for children under 5 requires three separate doses. Single dose vaccines counts are recorded in a separate column.

Summing the NEW_1ST_DOSES, NEW_2ND_DOSES, NEW_SINGLE_DOSES columns would give you the total count of primary vaccine series doses administered on a given day. To count the number of individuals who have completed their primary vaccine series on a given day, use the NEW_SERIES_COMPLETED column. To count the number of individuals vaccinated (with any primary series dose) for the first time on a given day, use the NEW_RECIPIENTS column.

To count the number of individuals who got a vaccine booster on a given day, use the NEW_BOOSTER_RECIPIENTS column. To count the number of booster doses administered on a given day, use the NEW_BOOSTER_DOSES column. To count the total number of individuals who have received a booster over time, use the CUMULATIVE_BOOSTER_RECIPIENTS column. To count the total number of booster doses that have been administered over time, use the CUMULATIVE_BOOSTER_DOSES column.

In our public dashboards we combine this dataset with the US Census's 2019 five-year American Community Survey population estimates to estimate the percent of San Franciscans vaccinated.